|
Press Room
2007 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
October 03, 2007
InNexus CEO to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference November 5,2007 In New York City
British Columbia, Canada - November 1, 2007 - Jeff Morhet, Chairman and Chief Executive Officer of InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX VENTURE: IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. The presentation will be on November 5, 2007 at 2:00PM ET in the Kennedy II Room at the New York Palace Hotel in New York City. Mr. Morhet will provide a company overview, including information about InNexus’ unique business strategy, its DXL™ technology platform and upcoming company milestones. The presentation will be web cast and available for replay after the presentation via the company’s website at www.ixsbio.com.
The conference will include presentations by over 350 companies, as well as experts from the medical, scientific and investment communities. Investors, venture capitalists, company executives, scientists and other industry leaders will attend the conference. A live audio webcast of this presentation can be accessed via Webcast-Link "http://www.wsw.com/webcast/rrshq12/ixs.cn". All slides from the presentation will be available for replay after the presentation.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL™ technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact
InNexus Biotechnology Inc.
Wade Brooksby, CFO
480-862-7500
The Investor Relations Group
Investor Relations:
Christine Berni/Joe Triunfo, 212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
Media:
Janet Vasquez/ Michaela Heller, 212-825-3210
jvasquez@investorrelationsgroup.com
mheller@investorrelationsgroup.com
|
|
|
